Patient Satisfaction and Quality of Life Impact - PecFent®

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.

• Study objectives include assessment of early treatment satisfaction.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Archimedes Development Ltd
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Adult (aged ≥18 years) with cancer

• Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain